NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
641 Västerbotten

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 97 11.7% 13 1.6% 7 0.8% 1 0.1% 1 0.1% . . 712 85.7% 831 100.0%
ASCUS 139 55.2% 54 21.4% 33 13.1% 1 0.4% 1 0.4% . . 24 9.5% 252 100.0%
LSIL 104 40.6% 74 28.9% 50 19.5% . . . . . . 28 10.9% 256 100.0%
Atypical glandular cells/AGC 7 50.0% 1 7.1% 5 35.7% . . 1 7.1% . . . . 14 100.0%
Unclear atypia 1 100.0% . . . . . . . . . . . . 1 100.0%
ASC-H 8 23.5% 5 14.7% 19 55.9% . . . . . . 2 5.9% 34 100.0%
HSIL 7 11.9% 3 5.1% 43 72.9% 2 3.4% 1 1.7% 1 1.7% 2 3.4% 59 100.0%
Suspected Adenocarcinom . . . . . . 1 100.0% . . . . . . 1 100.0%
Squamous cell cancer . . . . 1 50.0% . . 1 50.0% . . . . 2 100.0%
Totalt 363 25.0% 150 10.3% 158 10.9% 5 0.3% 5 0.3% 1 0.1% 768 53.0% 1450 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M81403